2.5 milliondeaths per year
are prevented by vaccines
5lives every minute
are saved by vaccines worldwide
2.5 milliondeaths per year
are prevented by vaccines
5lives every minute
are saved by vaccines worldwide
about
mAXVAX
Technology
& production
Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.
Learn moreTechnology
Platform
+
Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.
Learn morePipeline
Introduction
+
We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.
Learn more...Production
Capability
+
news
center
On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.
more >
Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.
more >
On June 28, 2024, Chengdu Maxvax Biotechnology LLC (hereinafter referred to as “Maxvax”) announced that its application for a clinical trial of a new vaccine - recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - has been approved by China’s Center for Drug Evaluation (CDE).
more >